ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Phase I/II clinical trial for its Anthrax Immune Globulin (AIG) therapeutic candidate has commenced with the initial treatment given to the first subject. AIG, which is intended for the treatment of inhalational anthrax disease, is the company’s polyclonal therapeutic candidate developed using plasma collected from healthy donors, who have been vaccinated with Emergent’s BioThrax® (Anthrax Vaccine Adsorbed), the only vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of anthrax infection.
